中医药分阶段防治恶性肿瘤术后复发转移优化方案探讨

doi:10.3736/jcim20070102

Abstract

Relapse and metastasis are the main causes responsible for failure of surgical operation in treating malignant tumors. This article introduces the present development in post-operation treatment of lung cancer, liver cancer and stomach cancer, showing that the synthetic treatment by stages combined with traditional Chinese medicine is the important way to prevent and treat the post-operation relapse and metastasis of tumors, and suggesting the optimized method for treatment.

Key words: traditional Chinese medicine, tumors, relapse, metastasis

CLC Number:

R730.1

Zhen-ye Xu, Zhan Zheng. An optimized 3-step strategy for preventing and treating post-operation relapse and metastasis of malignant tumors with traditional Chinese medicine. Journal of Chinese Integrative Medicine, 2007, 5(1): 5-10.

/ / Recommend

Add to citation manager EndNote| Reference Manager|ProCite|BibTeX|RefWorks

URL: http://www.jcimjournal.com/EN/10.3736/jcim20070102

http://www.jcimjournal.com/EN/Y2007/V5/I1/5

TrendMD

References 36

[1]	汤钊猷 . 现代肿瘤学(第2版)[M]. 上海: 上海医科大学出版社, 2000,( 第2版):254
	Tang ZY. Modern oncology(2nd ed)[M]. Shanghai: Shanghai Medical University Press, 2000,( 2nd ed):254
[2]	徐振晔, 杨宇飞 . 肺癌中西医综合治疗(第1版)[M]. 北京: 人民卫生出版社, 2002,( 第1版):541
	Xu ZY, Yang YF. Comprehensive treatment of lung cancer with traditional Chinese and Western medicine(1st ed)[M]. Beijing: People's Medical Publishing House, 2002,( 1st ed):541
[3]	Tanaka F, Wada H . Efficacy of postoperative adjuvant therapy for resected non-small cell lung cancer--an evidence-based review[J]. Gan To Kagaku Ryoho, 2006,33(3):300-306
[4]	Uramoto H, Kagami S, Iwashige A , et al. Chemotherapy for lung cancer patients[J]. J UOEH, 2006,28(1):75-84 doi: 10.7888/juoeh.28.75 pmid: 16541742
[5]	Schiller JH, Harrington D, Belani CP , et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer[J]. N Engl J Med, 2002,346(2):92-98
[6]	Barlesi F, Jacot W, Astoul P , et al. Second-line treatment for advanced non-small cell lung cancer: a systematic review[J]. Lung Cancer, 2006,51(2):159-172 doi: 10.1016/j.lungcan.2005.08.017 pmid: 16360238
[7]	Hanna N . Advances in the treatment of second-line non-small-cell lung cancer[J]. Lung Cancer, 2005,50(Suppl 1):S15-S17 doi: 10.1016/S0169-5002(05)81554-5 pmid: 16291425
[8]	De Marinis F, De Santis S, De Petris L . Second-line treatment options in non-small cell lung cancer: a comparison of cytotoxic agents and targeted therapies[J]. Semin Oncol, 2006,33(1 Suppl 1):S17-S24
[9]	Zinner RG, Fossella FV, Gladish GW , et al. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer[J]. Cancer, 2005,104(11):2449-2456
[10]	Dowell JE . Epidermal growth factor receptor mutations in non-small cell lung cancer: a basic science discovery with immediate clinical impact[J]. Am J Med Sci, 2006,331(3):139-149
[11]	Herbst RS, Giaccone G, Schiller JH , et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase Ⅲ trial--INTACT 2[J]. J Clin Oncol, 2004,22(5):785-794
[12]	Giaccone G, Herbst RS, Manegold C , et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase Ⅲ trial--INTACT 1[J]. J Clin Oncol, 2004,22(5):777-784
[13]	Belvedere O, Grossi F . Lung Cancer Highlights from ASCO 2005[J]. Oncologist, 2006,11(1):39-50 doi: 10.1634/theoncologist.11-1-39 pmid: 16401712
[14]	Belani CP, Ramalingam S . Bevacizumab extends survival for patients with nonsquamous non-small-cell lung cancer[J]. Clin Lung Cancer, 2005,6(5):267-268
[15]	Tyagi P . Bevacizumab, when added to paclitaxel/carboplatin, prolongs survival in previously untreated patients with advanced non-small-cell lung cancer: preliminary results from the ECOG 4599 trial[J]. Clin Lung Cancer, 2005,6(5):276-278
[16]	Bruix J, Llovet JM, Castells A , et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution[J]. Hepatology, 1998,27(6):1578-1583
[17]	Pelletier G, Ducreux M, Gay F , et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC[J]. J Hepatol, 1998,29(1):129-134
[18]	汤钊猷 . 汤钊猷临床肝癌学(第1版)[M]. 上海: 上海科技教育出版社, 2001,( 第1版):123
	Tang ZY. Tang Zhaoyou clinical hepatocarcinology(1st ed)[M]. Shanghai: Shanghai Scientific and Technical Education Publishing House, 2001,( 1st ed):123
[19]	Kretzschmar A, Schlag PM . Efficacy of current adjuvant and neoadjuvant therapeutic concepts in gastric cancer?[J]. Zentralbl Chir, 2006,131(2):121-125 doi: 10.1055/s-2006-921537 pmid: 16612778
[20]	Kodera Y, Fujiwara M, Koike M , et al. Chemotherapy as a component of multimodal therapy for gastric carcinoma[J]. World J Gastroenterol, 2006,12(13):2000-2005 doi: 10.1111/j.1365-2036.2006.02866 pmid: 16610047
[21]	Papakostas P, Tsavdaridis D, Kosmidis P , et al. Combination docetaxel(Taxotere), fluorouracil, and leucovorin(TFL), as first-line chemotherapy in advanced gastric cancer: a Hellenic Cooperative Oncology Group phase II study[J]. Gastric Cancer, 2006,9(1):26-31 doi: 10.1007/s10120-005-0353-4
[22]	张秀良, 徐淑峰, 徐鹏 , 等. 晚期胃癌姑息性术后腹腔热灌注化疗联合静脉化疗与单纯静脉化疗的临床观察[J]. 临床肿瘤学杂志, 2006,11(1):43-45
	Zhang XL, Xu SF, Xu P , et al. The study of intraperitoneal hyperthermic chemotherapy and intravenous chemotherapy after palliative operation for patients with advanced gastric carcinoma[J]. Lin Chuang Zhong Liu Xue Za Zhi, 2006,11(1):43-45
[23]	林黎明, 陈军, 苏妍 , 等. 胃癌术后腹腔热灌注化疗的临床应用[J]. 山东医药, 2005,45(16):35-36 doi: 10.3969/j.issn.1002-266X.2005.16.017
	Lin LM, Chen J, Su Y , et al. Clinical application of continuous hyperthermic peritoneal perfusion chemotherapy after operation for gastric carcinoma[J]. Shandong Yi Yao, 2005,45(16):35-36
[24]	严桂英, 徐振晔, 王中奇 , 等. 中药抗瘤增效方对非小细胞肺癌化疗增效减毒作用的临床研究[J]. 中华实用中西医杂志, 2005,18(6):873-876
	Yan GY, Xu ZY, Wang ZQ , et al. A clinical study on the synergic effect of chemotherapy combined with traditiona1 Chinese medicine Kangliu Zengxiao Fang in treatment of advanced non-small cell lung cancer[J]. Zhonghua Shi Yong Zhong Xi Yi Za Zhi, 2005,18(6):873-876
[25]	周卫东, 徐振晔, 王中奇 , 等. 抗瘤增效方对NSCLC化疗患者免疫功能及血清VEGF、CYFRA21-1的影响[J]. 上海中医药杂志, 2005,39(3):6-8
	Zhou WD, Xu ZY, Wang ZQ , et al. Effects of "Kangliu Zengxiao Decoction" on immunological functions and serum VEGF and CYFRA21-1 in patients with non-small cell lung cancer[J]. Shanghai Zhong Yi Yao Za Zhi, 2005,39(3):6-8
[26]	徐振晔, 朱晏伟, 周卫东 , 等. 双黄升白冲剂对化疗引起骨髓抑制的临床研究及小鼠骨髓超微结构的观察[J]. 中国中西医结合杂志, 2001,21(5):328-331
	Xu ZY, Zhu YW, Zhou WD , et al. Clinical and experimental study on effect of Shuanghuang Shengbai granule on myelosuppression induced by chemotherapy and ultrastructure observation of bone marrow in mice[J]. Zhongguo Zhong Xi Yi Jie He Za Zhi, 2001,21(5):328-331
[27]	张晖, 王中奇, 徐振晔 , 等. 双黄升白冲剂治疗肺癌化疗骨髓抑制82例分析[J]. 中医药学刊, 2003,21(7):1162-1163
	Zhang H, Wang ZQ, Xu ZY , et al. Treatment of chemotherapy-induced myelosuppression by Shuanghuang Shengbai Granules for patients with lung cancer: analysis of 82 cases[J]. Zhong Yi Yao Xue Kan, 2003,21(7):1162-1163
[28]	王中奇, 徐振晔 . 益气养精法治疗中晚期肺癌的探讨[J]. 上海中医药大学学报, 2002,16(4):30-31
	Wang ZQ, Xu ZY . Exploration of "qi-benefiting and essence-nourishing method" in the treatment of pulmonary cancer in middle and late stage[J]. Shanghai Zhong Yi Yao Da Xue Xue Bao, 2002,16(4):30-31
[29]	刘城林, 陈为平, 崔书中 , 等. 参芪扶正注射液辅助化疗治疗老年非小细胞肺癌临床观察[J]. 中国中西医结合杂志, 2004,24(10):901-903
	Liu CL, Chen WP, Cui SZ , et al. Effect of Shenqi Fuzheng injection for assistance of chemotherapy in treating senile patients with non-small cell lung cancer[J]. Zhongguo Zhong Xi Yi Jie He Za Zhi, 2004,24(10):901-903
[30]	赵兴 . 参芪扶正注射液减轻肿瘤放化疗毒副反应的临床观察[J]. 中国中西医结合杂志, 2004,24(9):857-858
	Zhao X . Clinical study of Shenqi Fuzheng Injection in relieving side reactions of radio-chemotherapy for tumor[J]. Zhongguo Zhong Xi Yi Jie He Za Zhi, 2004,24(9):857-858
[31]	余胜珠, 杨光华, 冯金梅 . 参芪扶正注射液联合化疗治疗恶性肿瘤86例临床观察[J]. 中西医结合学报, 2006,4(1):84-86
	Yu SZ, Yang GH, Feng JM . Clinical study on treatment of malignant neoplasms with Shenqi Fuzheng injection and chemotherapy[J]. Zhong Xi Yi Jie He Xue Bao, 2006,4(1):84-86
[32]	刘云霞, 匡唐洪, 蒋沈君 . 华蟾素注射液改善晚期癌症患者生活质量的临床观察[J]. 中国中医药科技, 2005,12(1):45-46
	Liu YX, Kuang TH, Jiang SJ . Clinical observation of cinobufacini injection in improving quality of life for patients with malignant tumor[J]. Zhongguo Zhong Yi Yao Ke Ji, 2005,12(1):45-46
[33]	陈燕平, 刘秀娟 . 华蟾素注射液配合化疗治疗晚期恶性肿瘤临床观察[J]. 实用中西医结合临床, 2003,3(2):18
	Chen YP, Liu XJ . Clinical observation of cinobufacini injection combined with chemotherapy in treating advanced malignant tumor[J]. Shi Yong Zhong Xi Yi Jie He Lin Chuang, 2003,3(2):18
[34]	臧爱华, 饶建华, 王志军 , 等. 康莱特在肺癌综合治疗中的作用[J]. 肿瘤防治研究, 2000,27(4):287-288
	Zang AH, Rao JH, Wang ZJ , et al. The effect of Kang Lai-te injection and multimodality therapy in primary lung lancer.[J]. Zhong Liu Fang Zhi Yan Jiu, 2000,27(4):287-288
[35]	王宇岭, 李道明, 徐红 , 等. 康莱特注射液联合化疗治疗晚期非小细胞肺癌[J]. 癌症进展杂志, 2005,3(3):274-275
	Wang YL, Li DM, Xu H , et al. Combination of Kanglaite injection and chemotherapy for treatment of advanced non-small cell lung cancer[J]. Ai Zheng Jin Zhan Za Zhi, 2005,3(3):274-275
[36]	张蕴萍 . 康莱特注射液治疗晚期肺癌的临床分析[J]. 现代肿瘤医学, 2003,11(3):237
	Zhang YP.Clinical analysis of Kanglaite injection for treatment of advanced lung cancer[J].Xian Dai Zhong Liu Yi Xue, 2003, 11(3):237. Chinese

Related Articles 15

[1]	Wan-jun Guo, Yi Wang, Yu Deng, Lin-yan Cheng, Xin Liu, Ruo-fan Xi, Sheng-jie Zhu, Xin-yi Feng, Liang Hua, Kan Ze, Jian-yong Zhu, Dong-jie Guo, Fu-lun Li. Therapeutic effects of the extract of Sancao Formula, a Chinese herbal compound, on imiquimod-induced psoriasis via cysteine-rich protein 61. Journal of Integrative Medicine, 2022, 20(4): 376-384.
[2]	Shang-jin Song, Xuan Liu, Qing Ji, Da-zhi Sun, Li-juan Xiu, Jing-yu Xu, Xiao-qiang Yue. Ziyin Huatan Recipe, a Chinese herbal compound, inhibits migration and invasion of gastric cancer by upregulating RUNX3 expression. Journal of Integrative Medicine, 2022, 20(4): 355-364.
[3]	Marisa Casal. Improving the health and treatment success rates of in vitro fertilization patients with traditional chinese medicine: need for more robust evidence and innovative approaches. Journal of Integrative Medicine, 2022, 20(3): 187-192.
[4]	Ning Guo, Fei Wu, Mei Wu, Yuan Wang, Qing Lang, Xiao Lin, Yi Feng. Progress in the design and quality control of placeboes for clinical trials of traditional Chinese medicine . Journal of Integrative Medicine, 2022, 20(3): 204-212.
[5]	Yan-jun Lin, Kun-li Jiao, Bo Liu, Lu Fang, Shu Meng. Antiplatelet and myocardial protective effect of shexiang tongxin dropping pill in patients undergoing percutaneous coronary intervention: A randomized controlled trial. Journal of Integrative Medicine, 2022, 20(2): 126-134.
[6]	Jia-jia Li, Qing Liang, Guang-chun Sun. Traditional Chinese medicine for prevention and treatment of hepatocellular carcinoma: A focus on epithelial-mesenchymal transition. Journal of Integrative Medicine, 2021, 19(6): 469-477.
[7]	Rui-jin Qiu, Min Li, Jia-yuan Hu, Jing Chen, Hong-cai Shang. Methods for development of a core outcome set for clinical trials integrating traditional Chinese medicine and Western medicine. Journal of Integrative Medicine, 2021, 19(5): 389-394.
[8]	Mao-xing Pan, Chui-yang Zheng, Yuan-jun Deng, Kai-rui Tang, Huan Nie, Ji-qian Xie, Dong-dong Liu, Gui-fang Tu, Qin-he Yang, Yu-pei Zhang. Hepatic protective effects of Shenling Baizhu powder, a herbal compound, against inflammatory damage via TLR4/NLRP3 signalling pathway in rats with nonalcoholic fatty liver disease . Journal of Integrative Medicine, 2021, 19(5): 428-438.
[9]	Ning Zhang, Xiao-he Xiao. Integrative medicine in the era of cancer immunotherapy: Challenges and opportunities. Journal of Integrative Medicine, 2021, 19(4): 291-294.
[10]	Thomas Efferth, An-long Xu, Roxana Damiescu, Mita Banerjee, Norbert W. Paul, David Y.W. Lee. Can eastern wisdom resolve western epidemics? Traditional chinese medicine therapies and the opioid crisis. Journal of Integrative Medicine, 2021, 19(4): 295-299.
[11]	Si-qi Tang, Yun-liang Wang, Zi-ye Xie, Yang Zhang, Yi Guo, Kang-li Gao, Tang-you Mao, Chun-e Xie, Jun-xiang Li, Xiao-yan Gao. Serum metabolic profiling of traditional Chinese medicine syndromes in patients with diarrhea-predominant irritable bowel syndrome. Journal of Integrative Medicine, 2021, 19(3): 274-281.
[12]	Miao-yan Shi, Shi-qi Sun, Wei Zhang, Xing Zhang, Gui-hua Xu, Xuan Chen, Zi-jian Su, Xiu-ming Song, Lu-jiong Liu, Yi-bao Zhang, Yi-le Zhang, Meng Sun, Qi Chen, Yan Xue, Hua Lü, Wei-an Yuan, Xiao-rong Chen, Yun-fei Lu. Early therapeutic interventions of traditional Chinese medicine in COVID-19 patients: a retrospective cohort study. Journal of Integrative Medicine, 2021, 19(3): 226-231.
[13]	Shu-jun Wei, Qing-man He, Qing Zhang, Kang-hua Fu, Ruo-lan Li, Wei Peng, Yong-xiang Gao. Traditional Chinese medicine is a useful and promising alternative strategy for treatment of Sjogren's syndrome: A review. Journal of Integrative Medicine, 2021, 19(3): 191-202.
[14]	Yi Xia, Lu-shao-bo Shi, Jing-hui Chang, Hua-zhang Miao, Dong Wang. Impact of the COVID-19 pandemic on intention to use traditional Chinese medicine: A cross-sectional study based on the theory of planned behavior. Journal of Integrative Medicine, 2021, 19(3): 219-225.
[15]	Na Zhi, Qian Mo, Shuo Yang, Yuan-xing Qin, Hao Chen, Zeng-guang Wu, Cai-hong Lan, Jun Zhang, Yin-long Li. Treatment of pulmonary fibrosis in one convalescent patient with corona virus disease 2019 by oral traditional Chinese medicine decoction: A case report. Journal of Integrative Medicine, 2021, 19(2): 185-190.

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed

Comments

Recommended 10

[1]	Jin-rong Fu. Establishment of multivariate diagnosis and treatment system of modern gynecology of traditional Chinese medicine. Journal of Chinese Integrative Medicine, 2008, 6(1): 22-24
[2]	Hao Li, Ming-jiang Yao, Wen-ming Zhao, Jie Guan, Lin-lin Cai, Ling Cui. A randomized, controlled, double-blind trial of Huannao Yicong capsule in senile patients with mild cognitive impairment. Journal of Chinese Integrative Medicine, 2008, 6(1): 25-31
[3]	Zhi-chun Jin. Problems in establishing clinical guideline for integrated traditional Chinese and Western medicine. Journal of Chinese Integrative Medicine, 2008, 6(1): 5-8
[4]	SUN Ming-yu, ZUO Jian, DUAN Ji-feng, HAN Jun, FAN Shi-ming, ZHANG Wei, ZHU Li-fang, YAO Ming-hui. Antitumor activities of kushen flavonoids in vivo and in vitro. Journal of Chinese Integrative Medicine, 2008, 6(1): 51-59
[5]	Min Cheng, Qiong Feng, Shu-wen Qian, Hui Gao, Cui-qing Zhu. Preliminary assay of p-amyloid binding elements in heart-beneficial recipe. Journal of Chinese Integrative Medicine, 2008, 6(1): 68-72
[6]	Ning-qun Wang, Liang-duo Jiang, Zong-xing Li. Research progress in asthma-related quality of life. Journal of Chinese Integrative Medicine, 2008, 6(1): 93-97
[7]	Jing-yuan Mao, Chang-xiao Liu, Heng-he Wang, Guang-li Wei , Zhen-peng Zhang, Jie Xing, Wang Xian liang , Ying-fei Bi . Effects of Shenmai Injection on serum concentration and pharmacokinetics of digoxin in dogs with heart failure. Journal of Chinese Integrative Medicine, 2010, 8(11): 1070-1074
[8]	Zhi-mei Wang, Bin Zhang. A study on translation of ellipses in Huangdi Neijing from perspective of hermeneutic theory. Journal of Chinese Integrative Medicine, 2010, 8(11): 1097-1100
[9]	Gui Yu, Jie Wang. Thinking on building the network cardiovasology of Chinese medicine. Journal of Chinese Integrative Medicine, 2012, 10(11): 1206-1210
[10]	Pedro Saganha João, Doenitz Christoph, Greten Tobias, Efferth Thomas, J. Greten Henry. Qigong therapy for physiotherapists suffering from burnout: a preliminary study. Journal of Chinese Integrative Medicine, 2012, 10(11): 1233-1239

An optimized 3-step strategy for preventing and treating post-operation relapse and metastasis of malignant tumors with traditional Chinese medicine

RichHTML

PDF (PC)

Like